The hungry bone: Expected and unexpected

Annali Italiani di Medicina Interna

Volumn 19, Issue 3, 2004, Pages

  Angeli, Alberto ^a   Dovio, Andrea ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM;

BLOOD; BONE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; METABOLISM; NOTE; SECONDARY HYPERPARATHYROIDISM; SYNDROME;

ALKALINE PHOSPHATASE; BONE AND BONES; CALCIUM; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOCALCEMIA; HYPOPHOSPHATEMIA; SYNDROME;

EID: 21644473252     PISSN: 03939340     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (20)

1. Grieff M. The hungry bone syndrome after medical treatment of thyrotoxicosis. Ann Intern Med 2003; 139: 706-7.
2. Frisch LS, Mimouni F. Hypomagnesemia following correction of metabolic acidosis: a case of hungry bones. J Am Coll Nutr 1993; 12: 710-3.
3. Bergkamp FJ, van Berkel AM, van der Linden PW, Gorgels JP. Unexpected prolonged extreme hypocalcaemia and an inadequate PTH response in a patient with metastatic breast carcinoma. Neth J Med 2003; 61: 371-5.
4. Riancho JA, Arjona R, Valle R, Sanz J, Gonzalez-Macias J. The clinical spectrum of hypocalcemia associated with bone metastases. J Intern Med 1989; 226: 449-52.
5. Murray RM, Grill V, Crinis N, Ho PW, Davison J, Pitt P. Hypocalcemia and normocalcemic hyperparathyroidism in patients with advanced prostate cancer. J Clin Endocrinol Metab 2001; 86: 4133-8.
6. Frost HM. The skeletal intermediary organization. Metab Bone Dis Rel Res 1983; 4: 281-90.
7. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-37.
8. Rosen CJ. What's new with PTH in osteoporosis: where are we and where are we headed? Trends Endocrinol Metab 2004; 15: 229-33.
9. Stilgren LS, Rettmer E, Eriksen EF, Hegedus L, Beck-Nielsen H, Abrahamsen B. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 2004; 35: 256-65.
10. Shinoda T, Aizawa T, Shirota T, et al. Exacerbation of latent heart failure by mild hypocalcemia after parathyroidectomy in a long-term emodialysis patient. Nephron 1992; 60: 482-6.
11. Falko JM, Bush CA, Tzagournis M, Thomas FB. Case report. Congestive heart failure complicating the hungry bone syndrome. Am J Med Sci 1976; 271: 85-9.
12. Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 1988; 84: 654-60.
13. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-25.
14. Morrone LF, Tampoia M, Pansini N, Gesualdo L. Kinetics of the circulating levels of bone alkaline phosphatase in a case of hungry bone disease following total parathyroidectomy. Ann Ital Med Int 2004; 19: 189-92.
15. Lo Cascio V, Rossini M, Bertoldo F. Il trattamento medico dell'iperparatiroidismo primitivo. Recenti Prog Med 1993; 84: 287-95.
16. Kumar A, Ralston SH. Bisphosphonates prevent the hungry bone syndrome [letter]. Nephron 1996; 74: 729.
17. Berruti A, Sperone P, Fasolis G, et al. Pamidronate administration improves the secondary hyperparathyroidism due to "bone hunger syndrome" in a patient with osteoblastic metastases from prostate cancer. Prostate 1997; 33: 252-5.
18. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 2001; 166: 2023-31.
19. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-64.
20. Cundy T, Davidson J, Stewart C, De Paoli A. Recombinant osteoprotegerin treatment potently inhibits bone resorption in subjects with osteoprotegerin deficiency [abstract]. J Bone Miner Res 2004; 19 (Suppl 1): 1103.